Declaración del consenso de la Sociedad Europea de Medicina Intensiva (ESICM) sobre el uso de coloides en el paciente crítico
Konrad R, Anders P, Charles L. S, Roman J. Consensus statement of the ESICM task force on colloid volume therapy in critically ill patients. Intensive Care Med (2012) 38:368–383.
DOI:
https://doi.org/10.30445/rear.v4i10.403Keywords:
Albúmina, coloides, grupo de trabajo, reanimaciónAbstract
El uso de cristaloides versus coloides en el paciente crítico ha sido desde hace años motivo de controversias. Actualmente se plantea un debate acerca de la efectividad relativa de los coloides comparados con los líquidos cristaloides (entradas anteriores albumina vs salino 0,9, o uso de la albumina en la resucitación). Las soluciones de coloides se utilizan cada vez más en la reanimación de pacientes en estado crítico, a pesar de que en las últimas revisiones de ensayos clínicos no se encontró pruebas de que los coloides reduzcan el riesgo de muerte comparado con los cristaloides.
Incluso la actual evidencia científica sugiere que los coloides pueden ser perjudiciales en algunos pacientes. Por lo tanto, la Sociedad Europea de Cuidados Intensivos (ESICM) reunió a un grupo de expertos para establecer recomendaciones del uso de coloides en pacientes críticos basados en la evidencia científica disponible.
References
2.- Perel P. Colloids versus crystalloids dor fluid resuscitation in critically ill patients. Cochrane Database Syst rev 2011; CD000567.
3.- The SAFE Study Investigators. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004 350; 2247-2256N.
4.- Delaney AP. The role of albumin as a resuscitation fluid for patients with sepsis: a systematic review and metaanalysis. Crit Care Med 2011 39:386–391.
5.- No authors listed] (1998) Department of Health and Human Services, Food and Drug Administration 1998; Docket No. 98N-0655. List of Drug Products That Have Been Withdrawn or Removed From the Market for Reasons of Safety or Effectiveness. Federal Register 1998: Vol 63, N 195: 54082-54089.
6.- Dart AB. Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function. Cochrane Database Syst Rev 2010: CD007594.
7. - Groeneveld AB. Update on the comparative safety of colloids: a systematic review of clinical studies. Ann Surg 2011 253:470–483.
8.-Zarychanski R. Renal outcomes and mortality following hydroxyethyl starch resuscitation of critically ill patients: systematic review and meta-analysis of randomized trials. Open Med 3 2003: E196–209.
9.- Hartog CS. A systematic review of third-generation hydroxyethyl starch (HES 130/0,4) in resuscitation: safety not adequately addressed. Anesth Analg 2011 112:635–645.
10.- Myburgh J. Saline or albumin for fluid resuscitation in patients with traumatic brain injury. N Engl J Med 2007 357:874–884.
11.- Schabinski F. Effects of a predominantly hydroxyethyl starch (HES)-based and a predominantly non HES-based fluid therapy on renal function in surgical ICU patients. Intensive Care Med 2009 35:1539–1547.
12.- Bayer O. Renal effects of synthetic colloids and crystalloids in patients with severe sepsis: a prospective sequential comparison. Crit Care Med 2011 39:1335–1342.
13.- Cittanova ML. Effect of hydroxyethylstarch in braindead kidney donors on renal function in kidney-transplant recipients. Lancet 1996 348:1620–1622.
14.- Brochard L. An official ATS/ERS/ESICM/SCCM/SRLF statement: prevention and management of acute renal failure in the ICU patient: an international consensus conference in intensive care medicine. Am J Respir Crit Care Med 2010 181:1128–1155.
15.- Wiedermann CJ. Hyperoncotic colloids and acute kidney injury: a meta-analysis of randomized trials. Crit Care 2010 14:R191.
16.- Schortgen F. The risk associated with hyperoncotic colloids in patients with shock. Intensive Care Med 2008 34:2157–2168.
Revista Electrónica AnestesiaR by 